Repositorio Dspace

Listar por tema "Immune Checkpoint Inhibitors/adverse effects/therapeutic use"

Listar por tema "Immune Checkpoint Inhibitors/adverse effects/therapeutic use"

Ordenar por:Orden:Resultados:

  • Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital 
    Juan-Carpena, Gloria; Martínez-Banaclocha, Natividad; Carlos-Palazon-Cabanes, Juan; Niveiro-de-Jaime, María; Betlloch-mas, Isabel; Blanes-Martínez, Mar (ACTA DERMATO-VENEREOLOGICA, 2025-01-03)
    Cutaneous immune-related adverse events (cirAEs) may be associated with tumoral response and survival in patients using immune checkpoint inhibitors, but this relationship remains unclear because previous reports on the ...
  • BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 
    Márquez-Rodas, Iván; Dutriaux, Caroline; Saiag, Philippe; de-la-Cruz-Merino, Luis; Castañon-Álvarez, Eduardo; Robert, Caroline; Rodríguez-Moreno, Juan-F; Arance, Ana; Cerezuela-Fuentes, Pablo; Montaudie, Henri; Fernández-de-Sanmamed-Girón, Miguel; González-Cao, María; Charles, Julie; López-Criado, María-Pilar; Berrocal, Alfonso; de-Miguel, Enrique; Funck-Brentano, Elisa; Prey, Sorilla; Álamo-de-la-Gala, María-del-Carmen; Melero, Ignacio; Avilés-Izquierdo, José-Antonio; Roman, Ruth; García-Pelaez, Beatriz; Rodríguez, Sonia; Trnkova, Zuzana-Jirakova; Quintero, Marisol; Macia, Sonia; Chaney, Marya-F; Dalle, Stephane (LIPPINCOTT WILLIAMS & WILKINS, 2025-09)
    PURPOSE: Patients with anti-PD-1-resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered intratumorally ...
  • Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) 
    González-Cao, María; Puertolas, Teresa; Riveiro, Mar; Muñoz-Couselo, Eva; Ortiz, Carolina; Paredes, Roger; Podzamczer, Daniel; Manzano, José-Luis; Molto, José; Revollo, Boris; Carrera, Cristina; Mateu, Lourdes; Fancelli, Sara; Espinosa, Enrique; Clotet, Bonaventura; Martínez-Picado, Javier; Cerezuela, Pablo; Soria, Ainara; Márquez, Ivan; Mandala, Mario; Berrocal, Alfonso (BMJ PUBLISHING GROUP, 2021)
    Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement ...
  • Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma 
    Aceituno, L; Magyar, C; Tabrizian, P; Marino, R; Watt, K; Chascsa, D; Schnickel, G; Banz, V; Alconchel-Gago, Felipe; Martagón-Mármol, Celia; Moctezuma, C; Baker, T; Nwaduru, C; Krendl, F-J; Oberhuber, R; Ruiz-ortega, L; Demers, C; Bucur, R; O'kane, G; Vogel, A; Mínguez, B; Sapisochin, G (WILEY, 2026-05)
    BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as promising agents for the management of advanced HCC. By reducing tumour burden, ICIs may serve as a downstaging/bridging tool to improve transplant candidacy. ...